← Back to home

COMBINATION OF FRUQUINTINIB AND ANTI-PD-1 ANTIBODY WAS REPORTED TO IMPROVE PATIENT PROGNOSIS IN COLORECTAL CANCER

Clinical trials for COMBINATION OF FRUQUINTINIB AND ANTI-PD-1 ANTIBODY WAS REPORTED TO IMPROVE PATIENT PROGNOSIS IN COLORECTAL CANCER explained in plain language.

Never miss a new study

Get alerted when new COMBINATION OF FRUQUINTINIB AND ANTI-PD-1 ANTIBODY WAS REPORTED TO IMPROVE PATIENT PROGNOSIS IN COLORECTAL CANCER trials appear

Sign up with your email to follow new studies for COMBINATION OF FRUQUINTINIB AND ANTI-PD-1 ANTIBODY WAS REPORTED TO IMPROVE PATIENT PROGNOSIS IN COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

Can a Three-Drug combo outsmart Hard-to-Treat colorectal cancer?

Disease control Recruiting now

This phase 2 trial is testing whether combining three drugs—fruquintinib, pirfenidone, and pembrolizumab—can help people with advanced or metastatic colorectal cancer that has not responded to standard treatments. The study includes 25 participants with a specific type of tumor (…

Matched conditions: COMBINATION OF FRUQUINTINIB AND ANTI-PD-1 ANTIBODY WAS REPORTED TO IMPROVE PATIENT PROGNOSIS IN COLORECTAL CANCER

Phase: PHASE2 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control

Last updated Aug 19, 2026 10:00 UTC

COMBINATION OF FRUQUINTINIB AND ANTI-PD-1 ANTIBODY WAS REPORTED TO IMPROVE PATIENT PROGNOSIS IN COLORECTAL CANCER

Get alerted when new COMBINATION OF FRUQUINTINIB AND ANTI-PD-1 ANTIBODY WAS REPORTED TO IMPROVE PATIENT PROGNOSIS IN COLORECTAL CANCER trials appear

Can a Three-Drug combo outsmart Hard-to-Treat colorectal cancer?